Internal Medicine, Hematology & Oncology · Huntsville, AL
NPI
1467689505
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
3601 Cci Dr NW
Huntsville, AL, 35805
Phone (256) 705-4224
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.6M
200,338 services
Medicare patients, 2024
956
Average age 74
Drug cost, 2024
$7.5M
1,610 prescriptions
Company payments, 2025
$17K
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ehab El-Bahesh was code J9271 (injection, pembrolizumab, 1 mg), 10,200 times for 17 patients. In total Ehab El-Bahesh billed 200,338 services in 203 codes, and Medicare paid $3.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 10,200 | 17 | $44.78 | $457K |
| J0897 Injection, denosumab, 1 mg | Office | 6,300 | 46 | $20.16 | $127K |
| J0185 Injection, aprepitant, 1 mg | Office | 5,590 | 17 | $1.35 | $7,547 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 4,590 | 15 | $2.24 | $10K |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,966 | 14 | $0.08 | $318 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,700 | 32 | $15.57 | $58K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,787 | 66 | $0.09 | $242 |
| 85025 Blood Count | Office | 1,892 | 802 | $7.54 | $14K |
| 36415 Venipuncture Blood Collection | Office | 1,840 | 768 | $8.65 | $16K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 1,830 | 11 | $32.14 | $59K |
| 80053 Clinical Chemistry | Office | 1,820 | 784 | $10.25 | $19K |
| 99214 Office E&M - Established | Office | 978 | 434 | $88.73 | $87K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 890 | 43 | $0.23 | $202 |
| 88185 Surgical Pathology Examination | Office | 864 | 34 | $15.98 | $14K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 860 | 26 | $0.25 | $213 |
By year: 2022 $3.7M for 253,176 services; 2023 $3.8M for 251,499 services; 2024 $3.6M for 200,338 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,892 | 802 | $7.54 | $14K |
| 36415 Venipuncture Blood Collection | 1,840 | 768 | $8.65 | $16K |
| 80053 Clinical Chemistry | 1,820 | 784 | $10.25 | $19K |
| 88185 Surgical Pathology Examination | 864 | 34 | $15.98 | $14K |
| 82728 Clinical Chemistry | 484 | 300 | $13.05 | $6,318 |
| 83550 Clinical Chemistry | 482 | 298 | $8.39 | $4,043 |
| 83540 Clinical Chemistry | 482 | 298 | $6.22 | $2,996 |
| 82607 Clinical Chemistry | 448 | 282 | $14.47 | $6,483 |
| 85046 Blood Count | 408 | 231 | $5.37 | $2,189 |
| 83883 Clinical Chemistry | 338 | 134 | $12.90 | $4,359 |
Medicare prescription drug claims, 2024
In 2024, the drug Ehab El-Bahesh prescribed most often to Medicare patients was Eliquis (Apixaban), with 126 prescriptions and refills. In total Ehab El-Bahesh wrote 1,610 Medicare prescriptions that cost $7.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 126 | 208 | 44 | $119K |
| Anastrozole Generic | 118 | 250 | 47 | $2,000 |
| Nubeqa Darolutamide | 112 | 112 | 16 | $1.5M |
| Orgovyx Relugolix | 88 | 92 | 12 | $254K |
| Ondansetron Hcl Generic | 58 | 59 | 39 | $713 |
| Dexamethasone Generic | 50 | 51 | 19 | $771 |
| Xtandi Enzalutamide | 49 | 49 | Under 11 | $658K |
| Revlimid Lenalidomide | 49 | 49 | Under 11 | $749K |
| Tagrisso Osimertinib Mesylate | 44 | 44 | Under 11 | $720K |
| Lenalidomide Generic | 43 | 43 | Under 11 | $466K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 42 | 42 | 19 | $597 |
| Udenyca Autoinjector Pegfilgrastim-Cbqv | 37 | 37 | Under 11 | $147K |
| Acyclovir Generic | 36 | 45 | Under 11 | $425 |
| Prednisone Generic | 36 | 36 | 11 | $140 |
| Kisqali Ribociclib Succinate | 34 | 34 | Under 11 | $468K |
Brand drugs: - claims; generic drugs: 871 claims; opioid claims: 78.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ehab El-Bahesh $17K ($17K in general payments such as food, travel and fees) from 36 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $9,724.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 13 | $9,724 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $5,058 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $188 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $181 |
| BeOne Medicines USA, Inc. ONC | 8 | $147 |
| Merck Sharp & Dohme LLC MRK | 6 | $134 |
| Sobi, Inc SOBI.ST | 1 | $116 |
| Adc Therapeutics America, Inc. | 1 | $115 |
| Daiichi Sankyo Inc. 4568.T | 5 | $114 |
| Celgene Corporation BMY | 4 | $86.46 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.